The BEND3 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal cell population in which the target gene BEND3 has been disrupted to generate a loss-of-function model. This product provides a heterogeneous pool of knockout cells derived from the HeLa host line, suitable for studying gene silencing, heterochromatin organization, and Wnt pathway modulation without clonal isolation artifacts. The polyclonal format preserves genetic diversity, enabling robust and reproducible phenotypic screening across a broad cellular background. Researchers can utilize these polyclonal knockout cells as a versatile tool for investigating BEND3-dependent transcriptional repression mechanisms in an immortalized cancer model system.
The host cell line is HeLa, a widely used human epithelial cell line originating from a cervical adenocarcinoma, which is positive for human papillomavirus type 18 (HPV18). In these cells, the tumor suppressor p53 is targeted for degradation by the HPV E6 oncoprotein, creating a permissive environment for studying oncogenic signaling. HeLa cells exhibit rapid proliferation and are well-adapted to a variety of standard cell culture and transfection protocols. Their immortalized nature and extensive use in cancer research make them an ideal background for probing the functional roles of chromatin organizers such as BEND3 in neoplastic contexts.
BEND3 (BEN domain-containing protein 3) functions as a transcriptional repressor that recruits histone deacetylases (HDAC1, HDAC2) and DNA methyltransferases (DNMT1) along with accessory members of the CoREST complex (SIN3A) to gene promoters, thereby promoting heterochromatin formation and long-term gene silencing. It directly interacts with polycomb group factors (EZH2, SUZ12) and corepressor modules, linking DNA methylation and histone modifications. Within the Wnt/??-catenin signaling cascade, BEND3 acts as a negative regulator by repressing downstream oncogenic targets such as MYC and CCND1. Its activity is modulated by TCF/LEF transcription factors and chromatin context, while loss of BEND3 function may relieve repression on Wnt-responsive genes, including those encoding cell cycle regulators.
In the HeLa cell background, disruption of BEND3 provides a physiologically relevant model to assess how loss of this repressor influences chromatin architecture and gene expression programs in a high-grade cancer context. The interplay between HPV-driven transformation and deregulation of Wnt/??-catenin signaling can be dissected using this knockout model. Given that BEND3 loss has been implicated in colorectal and cervical cancers, the BEND3 knockout HeLa polyclonal cells enable mechanistic studies linking chromatin remodeling defects to oncogenic gene activation, particularly through derepression of MYC and CCND1, thereby facilitating tumor cell proliferation and survival.
Typical applications for this polyclonal knockout cell population include chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to map BEND3-dependent histone modification patterns, RNA-sequencing to define the transcriptomic landscape upon loss of BEND3-mediated repression, and reporter gene assays to measure ??-catenin/TCF7L2 transcriptional activity. These cells are well-suited for western blotting to confirm target protein levels (e.g., MYC, CCND1) and for functional assays such as cell proliferation and migration studies. Additionally, they serve as a platform for screening epigenetic modifiers or compounds targeting HDACs and DNMTs. For further information regarding this CRISPR/Cas9-edited polyclonal knockout cell population, please contact Ascent Research.
